Cargando…
Le tocilizumab, un plus dans la Covid-19 sévère
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Masson SAS.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558630/ http://dx.doi.org/10.1016/S0992-5945(22)00173-8 |
| _version_ | 1784807482246299648 |
|---|---|
| author | Dalmat, Yann-Mickael |
| author_facet | Dalmat, Yann-Mickael |
| author_sort | Dalmat, Yann-Mickael |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9558630 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95586302022-10-16 Le tocilizumab, un plus dans la Covid-19 sévère Dalmat, Yann-Mickael Option/Bio Article Elsevier Masson SAS. 2022-09 2022-10-13 /pmc/articles/PMC9558630/ http://dx.doi.org/10.1016/S0992-5945(22)00173-8 Text en Copyright © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Dalmat, Yann-Mickael Le tocilizumab, un plus dans la Covid-19 sévère |
| title | Le tocilizumab, un plus dans la Covid-19 sévère |
| title_full | Le tocilizumab, un plus dans la Covid-19 sévère |
| title_fullStr | Le tocilizumab, un plus dans la Covid-19 sévère |
| title_full_unstemmed | Le tocilizumab, un plus dans la Covid-19 sévère |
| title_short | Le tocilizumab, un plus dans la Covid-19 sévère |
| title_sort | le tocilizumab, un plus dans la covid-19 sévère |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558630/ http://dx.doi.org/10.1016/S0992-5945(22)00173-8 |
| work_keys_str_mv | AT dalmatyannmickael letocilizumabunplusdanslacovid19severe |